Popular Articles

Pfizer Discontinues Phase 3 Trial Of Sutent(R) In Metastatic Colorectal Cancer
Pfizer Inc announced the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent® (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus FOLFIRI alone for the first-line treatment of metastatic colorectal cancer (CRC). The independent Data Monitoring Committee (DMC) found that the addition of sunitinib to the chemotherapy regimen FOLFIRI would be unable to demonstrate a statistically significant improvement in the primary endpoint of progression-free survival (PFS) compared to FOLFIRI alone, in this study. No new safety issues were identified.
generic viagra online
Brain's Object Recognition System Activated By Touch Alone
Portions of the brain that activate when people view pictures of objects compared to scrambled images can also be activated by touch alone, confirms a new report published online on May 28th in Current Biology, a Cell Press publication.
News of the day
Examining The Risk Of Tuberculosis From Arthritis Medication
Treatment with anti-tumor necrosis factor (TNF) agents is recognized as a risk factor for tuberculosis (TB) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn"s disease, psoriatic arthritis and psoriasis. Most TB cases develop as a result of reactivation of a latent TB infection, and health authorities worldwide recommend screening for latent TB and treating patients before initiating anti-TNF treatment. A new study examined cases of TB associated with anti-TNF therapy and found that the risk of TB is higher for patients receiving anti-TNF monoclonal antibody therapy (infliximab or adalimumab) than for those receiving soluble TNF receptor therapy (etanercept). The study is published in the July issue of Arthritis & Rheumatism.
Nutrition

Hear! Hear! Texas Wines Fight Cancer Growth

It"s happy hour for Texas wineries. Research now shows that wines produced in the Lone Star State share the anti-cancer traits known to exist in wines from other producing regions. Extracts from two Texas red wines decreased cancer cell growth in a comparable magnitude as other wines previously studied, according to Dr. Susanne Talcott, Texas AgriLife Research food and nutrition scientist. Her study, which concluded in May, showed decreased growth of colon and breast cancer cells treated with port and syrah (or shiraz) wine. It was the first such study of the health components of Texas wines, she said. "These results could definitely be projected to all Texas wines containing similar amounts of bioactive compounds," Talcott said. "And this will be the basis for a continued intensive study of all the health benefits of wines made in this state." Talcott presented her findings at the recent Texas Viticulture and Enology Research Symposium. She said the findings suggest that people who consume regular, moderate amounts of Texas wine daily -- up to a glass and a half -- may profit from similar health benefits ascribed to wines from other regions. "In general, studies show that wine may either prevent cells from mutating into cancer cells, or stop existing cancer cells from growing and causing them to die," Talcott noted. The scientific reasons behind her findings don"t exactly make easy party talk, so think of it this way: wines interact with a newly discovered class of molecules in cancer cells, called micro RNAs, a type of nucleic acid associated with chemical activities in a cell. Some of those micro RNAs are involved in causing cancer. Compounds in wine can go after these molecules like cops chasing criminals down a dark alley. In general, cancer cells merrily proliferate unregulated until the wine compounds interact and "arrest" the cancer cells, causing them to die, Talcott explained. The compounds also may work to prevent cancer, she said. The study of the health aspects of Texas wines may coincide with an anticipated continued rise in consumption, according to marketing analysts. Total wine consumption increased in Texas by 1.25 percent in 2007, according to Natalia Kolyesnikova, at the Texas Wine Marketing Research Institute at Texas Tech University. In the U.S., wine consumption is expected to increase from 292.1 million to 321.5 million cases by 2012. "If Texas follows this pattern, Texas wine consumption should expect to see similar growth patterns," Kolyesnikova reported. Talcott now will begin a more intense study of the health components of Texas wines, including clinical trials and benefits on other ailments such as cardiovascular disease. "We will not be short in study participants," she noted. She also plans a monthly news briefing on the health of Texas wines to the state"s 177 wineries and is available to speak at events and wine tasting rooms to share information on health benefits of wines and specifically Texas wines with the public. Notes: The Texas wine studies are part of a project funded by the Texas Department of Agriculture to improve the state"s grapes and wine production and to promote consumption of Texas wines. Additional information about the Texas wine research and education efforts can be found at http://winegrapes.tamu.edu/ or at http://www.gotexanwine.org/. Kathleen Phillips Texas A&M AgriLife Communications


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):